Azacitine (vidaza) for myelodysplastic syndrome.
Azacitidine is a new drug with a novel mechanism of action; it can correct abberant gene expression in patients with myelodysplastic syndrome. The drug improves symptoms, decreases the need for transfusions, reduced the rate of transformation to leukemia and probably improves survival.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine